Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YL217 |
Synonyms | |
Therapy Description |
Limited information is currently available on YL217, a putative antibody-drug conjugate (ADC) targeting CDH17 (Mar 2025). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YL217 | YL-217|YL 217 | Limited information is currently available on YL217, a putative antibody-drug conjugate (ADC) targeting CDH17 (Mar 2025). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06859762 | Phase I | YL217 | A First-in-Human Study of YL217 in Patients with Advanced Solid Tumors | Not yet recruiting | USA | 0 |